Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4397311 | 0.98 | CTSD (0.30) | CTSDCTSLCTSBCTSSFABP4 | |
| SCHEMBL1770349 | 0.96 | CTSD (0.31) | CTSDCTSLCTSBCTSSFABP4 | |
| SCHEMBL1771222 | 0.93 | FABP4 (0.35) | CTSDCTSLCTSBCTSSFABP4 | |
| SCHEMBL31536753 | 0.86 | USP2 (0.38) | CTSDCTSLCTSBCTSSASGR1 | |
| SCHEMBL2746258 | 0.85 | FABP4 (0.31) | FABP4 | |
| SCHEMBL30049388 | 0.84 | CTSD (0.30) | CTSDCTSLCTSBCTSS | |
| SCHEMBL2745088 | 0.83 | MT-CO2 (0.33) | FABP4ASGR1 | |
| SCHEMBL7019111 | 0.83 | NPSR1 (0.37) | — | |
| SCHEMBL24937070 | 0.82 | USP2 (0.36) | CTSDCTSLCTSBCTSSASGR1 | |
| SCHEMBL15116608 | 0.82 | CTSD (0.31) | CTSDCTSLCTSBCTSSASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2023137223-A1 | PAN-KRAS INHIBITORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022271823-A1 | MUTANT KRAS MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CTSD 2247/4885CTSL 1797/4885CTSB 2004/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CTSD 2247/4885CTSL 1797/4885CTSB 2004/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CTSD 2247/4885CTSL 1797/4885CTSB 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.